Stay updated on Zibotentan/Dapagliflozin Combo in Liver Cirrhosis Clinical Trial
Sign up to get notified when there's something new on the Zibotentan/Dapagliflozin Combo in Liver Cirrhosis Clinical Trial page.

Latest updates to the Zibotentan/Dapagliflozin Combo in Liver Cirrhosis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA new revision v3.7.0 was added to the study record history, and the previous revision v3.6.6 was removed from the list.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe history page now displays Revision: v3.6.6 instead of Revision: v3.6.5, reflecting a small software update.SummaryDifference0.1%

- Check43 days agoChange DetectedA newer revision label v3.6.5 appears in the history, replacing the previous revision v3.6.4. This indicates a page version update rather than changes to the study data or descriptions.SummaryDifference0.1%

- Check50 days agoChange DetectedVersion 28 was submitted on 2026-07-06, updating the study record with changes to key sections such as Adverse Events, Baseline Characteristics, Outcome Measures, and Study Status. A subsequent 2026-07-29 entry indicates the record was Returned with a Quality Control Review Has Not Concluded, highlighting ongoing QC on the latest data.SummaryDifference0.6%

- Check57 days agoChange DetectedThe study history page now shows a new site revision, v3.6.4, in place of the previous v3.6.3. This appears to be a front-end update to the page and does not modify the trial's records or content.SummaryDifference0.1%

- Check86 days agoChange DetectedThe revision history now lists a new revision (v3.6.3) and removes the older v3.6.0 entry, updating the shown list of revisions for the record.SummaryDifference0.1%

Stay in the know with updates to Zibotentan/Dapagliflozin Combo in Liver Cirrhosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Zibotentan/Dapagliflozin Combo in Liver Cirrhosis Clinical Trial page.